[
  {
    "ts": null,
    "headline": "BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business",
    "summary": "Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.",
    "url": "https://finnhub.io/api/news?id=8b3464b7f2d259216dcda2c08b44b2e1b1068f164e3d9df2c16bd102873eee86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735919580,
      "headline": "BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business",
      "id": 132255244,
      "image": "https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.",
      "url": "https://finnhub.io/api/news?id=8b3464b7f2d259216dcda2c08b44b2e1b1068f164e3d9df2c16bd102873eee86"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Retain Inari Medical Stock in Your Portfolio for Now",
    "summary": "NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.",
    "url": "https://finnhub.io/api/news?id=ac0e1afb6fcc8bae5400e22dd8fbd98de23c5a166702ee2d2dd1530a92d0b600",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735910880,
      "headline": "Reasons to Retain Inari Medical Stock in Your Portfolio for Now",
      "id": 132253903,
      "image": "https://media.zenfs.com/en/zacks.com/b66321e586fa6fdc44309f696ff0a17a",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.",
      "url": "https://finnhub.io/api/news?id=ac0e1afb6fcc8bae5400e22dd8fbd98de23c5a166702ee2d2dd1530a92d0b600"
    }
  },
  {
    "ts": null,
    "headline": "5 Non-Tech Outperformers of 2024 Set to Fly Higher in the Near Term",
    "summary": "Five non-technology high-flyers of 2024 have the potential to fly higher in the short term. These are: CMG, IBKR, KKR, FI, BSX.",
    "url": "https://finnhub.io/api/news?id=d3dde70d949b0a30873a661a6950bc05f9ca198f82026b60259b0e08cd414f00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735909380,
      "headline": "5 Non-Tech Outperformers of 2024 Set to Fly Higher in the Near Term",
      "id": 132254816,
      "image": "https://media.zenfs.com/en/zacks.com/1ac3a34a37b16e9f87da875db766e77c",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Five non-technology high-flyers of 2024 have the potential to fly higher in the short term. These are: CMG, IBKR, KKR, FI, BSX.",
      "url": "https://finnhub.io/api/news?id=d3dde70d949b0a30873a661a6950bc05f9ca198f82026b60259b0e08cd414f00"
    }
  },
  {
    "ts": null,
    "headline": "Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?",
    "summary": "PAHC shares gain owing to the remarkable performance of the Animal Health business and potential in the emerging markets.",
    "url": "https://finnhub.io/api/news?id=fc01d26636ee562888c2faf420f3eb5f4ecd6594f24e86cb160f2f36a68fb5b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735905300,
      "headline": "Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?",
      "id": 132252858,
      "image": "https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "PAHC shares gain owing to the remarkable performance of the Animal Health business and potential in the emerging markets.",
      "url": "https://finnhub.io/api/news?id=fc01d26636ee562888c2faf420f3eb5f4ecd6594f24e86cb160f2f36a68fb5b8"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific price target raised to $100 from $95 at Evercore ISI",
    "summary": "Evercore ISI analyst Vijay Kumar raised the firm’s price target on Boston Scientific (BSX) to $100 from $95 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly",
    "url": "https://finnhub.io/api/news?id=de834ee91bb21943bafafe15e65e64851ae6d6d644b237f8d0eacf8a2ab60674",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735904807,
      "headline": "Boston Scientific price target raised to $100 from $95 at Evercore ISI",
      "id": 132252859,
      "image": "https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Evercore ISI analyst Vijay Kumar raised the firm’s price target on Boston Scientific (BSX) to $100 from $95 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly",
      "url": "https://finnhub.io/api/news?id=de834ee91bb21943bafafe15e65e64851ae6d6d644b237f8d0eacf8a2ab60674"
    }
  }
]